<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Eighteen patients (pts) with <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) were treated with thymopentin (TP) (50 mg subcutaneously for 5 days) and recombinant interferon alpha 2a (rIFN alpha 2a) (3 MU/m2 subcutaneously on the sixth day); the courses were delivered every week </plain></SENT>
<SENT sid="1" pm="."><plain>Moreover those pts with &gt; or = 10% blasts in the bone marrow were additionally treated with low dose <z:chebi fb="1" ids="16040">cytosine</z:chebi> <z:chebi fb="0" ids="22601">arabinoside</z:chebi> (LDARAc) (20 mg standard dose, subcutaneously, twice a day for seven days every four weeks) </plain></SENT>
<SENT sid="2" pm="."><plain>Sixteen pts were finally assessable for response </plain></SENT>
<SENT sid="3" pm="."><plain>Seven pts (44%) were classified as good responders, 5 (31%) had a PR; the overall response rate (GR+PR) was 75% </plain></SENT>
<SENT sid="4" pm="."><plain>Two pts (12.5%) showed stable disease and the 2 remaining (12.5%) had progressive disease </plain></SENT>
<SENT sid="5" pm="."><plain>Six pts with an initial moderate <z:hpo ids='HP_0001903'>anemia</z:hpo> never required supportive care before and during the therapy; in contrast to 10 pts who were transfusion-dependent </plain></SENT>
<SENT sid="6" pm="."><plain>After six months of therapy 2 pts decreased their transfusional needs by 50% (1 of them did not receive any transfusion over the following six months of therapy); 2 pts needed no packed red cell infusions and 1 pt decreased his transfusional support by 75% </plain></SENT>
<SENT sid="7" pm="."><plain>Five pts kept an unchanged supportive care load </plain></SENT>
<SENT sid="8" pm="."><plain>The overall median survival was 12.5 months </plain></SENT>
<SENT sid="9" pm="."><plain>Therapy was generally well tolerated with acceptable compliance; the most frequently recorded side effects were <z:hpo ids='HP_0001875'>neutropenia</z:hpo> and <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo> grade 2-3 among the group receiving LDARAc </plain></SENT>
<SENT sid="10" pm="."><plain>However no life-threatening infectious episodes or <z:mp ids='MP_0001914'>bleeding</z:mp> were observed </plain></SENT>
<SENT sid="11" pm="."><plain>TP, rIFN alpha 2a and LDARAc can be safely administered on an outpatient basis to <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> pts and appears to have significant activity.(ABSTRACT TRUNCATED AT 250 WORDS) </plain></SENT>
</text></document>